The Board of Directors
The Board of Directors currently has ten members, of whom seven are elected by shareholders at shareholders’ meetings, and three are Novozymes employees from Denmark, elected by Danish employees.
On behalf of the shareholders, the Board of Directors determines the overall strategy and actively contributes to developing the company as a focused global industrial biotechnology company. The Board of Directors supervises the Executive Leadership Team in its decisions and operations and may issue new shares or buy back shares in accordance with authorizations granted by the shareholders meeting and recorded in the minutes.
The guiding principle in composing the Board of Directors is that it should comprise individuals whose particular knowledge and experience enables the Board of Directors as a whole to attend to the interests of shareholders, employees and other stakeholders.